• TechCrunch
• CrunchBase
• More
  • TechCrunch Europe
  • TechCrunch France
  • TechCrunch Japan

Cellectar

edit

Cellectar, Inc., a radiopharmaceutical company, designs and develops products to detect, treat, and monitor various human cancers. Its products include 131I-CLR1404, a compound for cancer therapy. The company�s product candidates combine lipid-like molecules and phospholipid ethers analogs with radioisotopes to image or destroy malignant cells. Cellectar, Inc. was formerly known as Cellectar, LLC and changed its name in 2008. The company was founded in 2003 and is based in Madison, Wisconsin.

Recent Milestones

edit

• 
  Cellectar was acquired by Novelos Therapeutics. (4/11/11)
  Posted 4/11/11 at 7:53pm via novelos.com

Videos

Screenshots

edit

Sources

1. NOVELOS THERAPEUTICS COMPLETES ACQUISITION AND $5.1 MILLION FINANCING TO DEVELOP 3 NOVEL CANCER-TARGETED COMPOUNDS (novelos.com) [edit]